透视图(图形)
偏头痛
化学
心理治疗师
神经科学
医学
心理学
精神科
计算机科学
人工智能
作者
Ezgi Pehlivanlar,Simone Carradori,Rahime Şimşek
出处
期刊:ACS pharmacology & translational science
[American Chemical Society]
日期:2024-03-16
卷期号:7 (4): 951-966
标识
DOI:10.1021/acsptsci.3c00370
摘要
Migraine is a disease of neurovascular origin that affects the quality of life of more than one billion people and ranks sixth among the most common diseases in the world. Migraine is characterized by a moderate or severe recurrent and throbbing headache, accompanied by nausea, vomiting, and photo-phonophobia. It usually starts in adolescence and is twice as common in women as in men. It is classified as with or without aura and has chronic or acute treatment types according to the frequency of occurrence. In acute treatment, analgesics that relieve pain in the fastest way are preferred, while there are different options in chronic treatment. While non-specific methods were used in the treatment of migraine until the 1950s, triptans, ditans, and CGRP-receptor-dependent therapies (monoclonal antibodies and gepants) started to be used in the clinic more recently. In this Review, we focus on the synthesis, side effects, and pharmacological and pharmacokinetic properties of FDA-approved drugs used in acute and preventive-specific treatment of migraine.
科研通智能强力驱动
Strongly Powered by AbleSci AI